Jorge Pedro Leguizamo MD
Hematology Director, Laboratory Director ,and Clinical Trials Sub-investigator at Georgia Cancer Specialists
Join to View Full Profile
698 Duluth HwySte 201Lawrenceville, GA 30046
Phone+1 770-822-0788
Fax+1 770-822-0326
Dr. Leguizamo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Jorge Leguizamo, MD is an Oncologist based in Lawrenceville, GA with a vast knowledge and experience in diagnosing and treating patients suffering from conditions such as amyloidosis, hematologic oncology, hereditary breast/ovarian cancer, myelodysplasia, and myelofibrosis. He completed his medical education in 1995 at Columbia University and continued further studies at Naval Medical Center in San Diego and National Capital Consortium. Throughout his career, he has made significant contributions to various scientific publications, particularly in the fields of atypical hemolytic uremic syndrome and solid tumors therapy. Dr. Leguizamo also received the CMS Meaningful Use Stage 1 Certification from NextGen Ambulatory EHR in 2013.
Education & Training
National Capital ConsortiumFellowship, Hematology and Medical Oncology, 1999 - 2002
Naval Medical Center (San Diego)Residency, Internal Medicine, 1997 - 1999- Naval Medical Center (San Diego)Internship, Internal Medicine, 1995 - 1996
Columbia University Vagelos College of Physicians and SurgeonsClass of 1995
Certifications & Licensure
GA State Medical License 2008 - 2026
NY State Medical License 1997 - 2026
MA State Medical License 2005 - 2009
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013
Publications & Presentations
PubMed
- 6 citationsTreatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome.Teri J Mauch, Michael R Chladek, Spero Cataland, Shruti Chaturvedi, Bradley P Dixon
Journal of Comparative Effectiveness Research. 2023-09-01 - 6 citationsA phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult p...Maurice A. Wright, Geraldine Morrison, Pengxin Lin, Gregory D. Leonard, Dat Nguyen
Clinical Cancer Research. 2005-06-01 - 7 citationsA phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion.Jorge P. Leguizamo, Mary G. Quinn, Chris H. Takimoto, Michael D. Liang, Abdel Salam Attia Ismail
Cancer Chemotherapy and Pharmacology. 2003-06-18
Professional Memberships
- Member
- Member
- International PNH interest groupMember
- Fellow
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
